Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects

Advancell and Neurotec Pharma have announced the initiation of a European Phase IIa clinical trial of NT-KO-003 for multiple sclerosis. Unlike other MS medications that act by immunosuppression, their therapeutic demonstrated both anti-inflammatory and neuroprotective effects in animal models, making it one of the first oral treatments that can both slow the progression and reduce the neurological damage caused by the disease. Given its neuroprotective properties, Advancell and Neurotec hope to explore the possibility of using NT-KO-003 to treat other neuromuscular diseases such as ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail